Endo Pharmaceuticals reaches patent litigation settlement with LecTec

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 11 2009Endo Pharmaceuticals

Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

Endo Pharmaceuticals has agreed to make a one-time, $23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. "We are pleased to add these patents to our IP inventory especially as they relate to Lidoderm®," said Caroline Manogue, executive vice president and chief legal officer of Endo Pharmaceuticals.

Source:

Endo Pharmaceuticals

Posted in: Medical Patent News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Georgetown study raises concerns over aspirin's role in breast cancer treatment
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Study highlights growing burden of neurological disorders worldwide
Extended CPAP treatment boosts lung development in premature infants
Study highlights global fertility decline and its implications for the future

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases